사이클린 의존성 인산화효소 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "사이클린 의존성 인산화효소" in Korean language version.

refsWebsite

Global rank Korean rank

2^nd place

3^rd place

4^th place

6^th place

18^th place

1,684^th place

647^th place

447^th place

433^rd place

archive.org

“FDA Grants Palbociclib Accelerated Approval for Advanced Breast Cancer”. 《National Cancer Institute》 (영어). 2017년 11월 30일에 확인함.

Lee MG, Nurse P (1987). “Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2”. 《Nature》 327 (6117): 31–5. doi:10.1038/327031a0. PMID 3553962.
Morgan DO (March 1995). “Principles of CDK regulation”. 《Nature》 374 (6518): 131–4. doi:10.1038/374131a0. PMID 7877684.
Morgan DO (1997). “Cyclin-dependent kinases: engines, clocks, and microprocessors”. 《Annual Review of Cell and Developmental Biology》 13: 261–91. doi:10.1146/annurev.cellbio.13.1.261. PMID 9442875.
Nebreda AR (April 2006). “CDK activation by non-cyclin proteins”. 《Current Opinion in Cell Biology》 18 (2): 192–8. doi:10.1016/j.ceb.2006.01.001. PMID 16488127.
Rossi AG, Sawatzky DA, Walker A, Ward C, Sheldrake TA, Riley NA, 외. (September 2006). “Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis”. 《Nature Medicine》 12 (9): 1056–64. doi:10.1038/nm1468. PMID 16951685.
Senderowicz AM (1999). “Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials”. 《Investigational New Drugs》 17 (3): 313–20. doi:10.1023/a:1006353008903. PMID 10665481.
Sausville EA (2002). “Complexities in the development of cyclin-dependent kinase inhibitor drugs”. 《Trends in Molecular Medicine》 8 (4 Suppl): S32–7. doi:10.1016/s1471-4914(02)02308-0. PMID 11927285.

Research, Center for Drug Evaluation and (2019년 2월 9일). “FDA approves abemaciclib for HR-positive, HER2-negative breast cancer”. 《FDA》 (영어).

Lee MG, Nurse P (1987). “Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2”. 《Nature》 327 (6117): 31–5. doi:10.1038/327031a0. PMID 3553962.
Morgan DO (March 1995). “Principles of CDK regulation”. 《Nature》 374 (6518): 131–4. doi:10.1038/374131a0. PMID 7877684.
Morgan DO (1997). “Cyclin-dependent kinases: engines, clocks, and microprocessors”. 《Annual Review of Cell and Developmental Biology》 13: 261–91. doi:10.1146/annurev.cellbio.13.1.261. PMID 9442875.
Nebreda AR (April 2006). “CDK activation by non-cyclin proteins”. 《Current Opinion in Cell Biology》 18 (2): 192–8. doi:10.1016/j.ceb.2006.01.001. PMID 16488127.
Rossi AG, Sawatzky DA, Walker A, Ward C, Sheldrake TA, Riley NA, 외. (September 2006). “Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis”. 《Nature Medicine》 12 (9): 1056–64. doi:10.1038/nm1468. PMID 16951685.
Senderowicz AM (1999). “Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials”. 《Investigational New Drugs》 17 (3): 313–20. doi:10.1023/a:1006353008903. PMID 10665481.
Sausville EA (2002). “Complexities in the development of cyclin-dependent kinase inhibitor drugs”. 《Trends in Molecular Medicine》 8 (4 Suppl): S32–7. doi:10.1016/s1471-4914(02)02308-0. PMID 11927285.